Veana Therapeutics, Inc.

Veana is a privately-held clinical stage biotechnology company developing effective and safer treatments for cancer patients

  • Stage Product In Development
  • Industry Biotechnology
  • Location Portland, OR 97207, USA
  • Currency USD
  • Founded July 2012
  • Employees 4
  • Incorporation Type C-corp
  • Website veana-therapeutics.com

Company Summary

Veana Therapeutics has an oral drug (VT-101) destabilizing tumor cells inducing apoptotic and immunogenic cancer cell death. Veana completed a successful Phase I monotherapy clinical trial in cancer patients where disease was stabilized in ~70% of patients who failed ALL previous therapies and has positive results in a trial at Fred Hutch (VT-101 with Herceptin) in HER2+ breast cancer patients. Veana's exit will be via Biopharma acquisition.

Team

  • Emmanuel Akporiaye

  • Patricia Beckmann
    Incoming CEO

    Dr. Patricia Beckmann has been Managing Director of BioStrategy LLC with over 30+ years experience as an entrepreneur, strategic business advisor, board member, venture investor and scientist. She is co-inventor of Immunex/Amgen’s Enbrel (2020 worldwide sales >$6B), has 50+ publications and 40+ issued U.S. Patents. She also serves on the Board of NACIE - as an entrepreneur advisor to the U.S. Secretary of Commerce.

Previous Investors

  • Elevate Capital
    Unconfirmed
    Mary Wheeler, BioRock Ventures
    Unconfirmed

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free